Shaigan Pharmaceuticals (Pvt) Ltd
Private pharmaceutical manufacturer · Rawalpindi · Pakistan
Rawalpindi-based pharmaceutical manufacturer focused on branded generic medicines, quality systems and international market expansion.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Shaigan Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 14-km, Adyala Road, Post Office Dahgal, Rawalpindi, Pakistan
- Website
- shaigan.com ↗
- Phone
- +92 51 5133060-8
- info@shaigan.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 1's | 033666 | PKR 208.60 | PKR 208.60/vial/unit | 9% above median |
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 10's | 033666 | PKR 1,756.63 | PKR 175.66/vial/unit | 9% below median |
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 5's | 033666 | PKR 878.32 | PKR 175.66/vial/unit | 9% below median |
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 50's | 045571 | PKR 8,783.15 | PKR 175.66/vial/unit | 9% below median |
| Celtis-250 | Ceftriaxone | 250 mg | IM injection | 1's | 045571 | PKR 208.60 | PKR 208.60/vial/unit | 6% above median |
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 10's | 045571 | PKR 1,756.63 | PKR 175.66/vial/unit | 9% below median |
| Celtis-250 | Ceftriaxone | 250 mg | Injection | 5's | 045571 | PKR 878.32 | PKR 175.66/vial/unit | 9% below median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 50's | 033665 | PKR 14,783.49 | PKR 295.67/vial/unit | 10% below median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 1's | 033665 | PKR 351.10 | PKR 351.10/vial/unit | 8% above median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 10's | 033665 | PKR 2,956.69 | PKR 295.67/vial/unit | 10% below median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 5's | 033665 | PKR 1,478.35 | PKR 295.67/vial/unit | 10% below median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 50's | 045573 | PKR 14,783.49 | PKR 295.67/vial/unit | 10% below median |
| Celtis-500 | Ceftriaxone | 500 mg | IM injection | 1's | 045573 | PKR 351.10 | PKR 351.10/vial/unit | 6% above median |
| Celtis-500 | Ceftriaxone | 500 mg | Injection | 5's | 045573 | PKR 1,478.35 | PKR 295.67/vial/unit | 10% below median |
| Cliver | Cefotaxime | 250 mg | Injection | 1's | 034218 | PKR 110.89 | PKR 110.89/vial/unit | 5% above median |
| Cliver | Cefotaxime | 500 mg | Injection | 1's | 034219 | PKR 170.62 | PKR 170.62/vial/unit | 7% above median |
| Cliver | Cefotaxime | 1000 mg | Injection | 1's | 034220 | PKR 300.58 | PKR 300.58/vial/unit | 5% above median |
| Clovir | Aciclovir | 200 mg/5 mL | Suspension | 60ml | 025947 | PKR 380.55 | PKR 6.34/mL | 23% above median |
| Clovir | Aciclovir | 200 mg | Tablet | 25's | 025948 | PKR 1,034.02 | PKR 41.36/tablet | 15% above median |
| Clovir | Aciclovir | 5 % | Cream | 10gm | 025949 | PKR 501.95 | PKR 50.20/g | 44% above median |
| Clozox | Clotrimazole | 100 mg | Tablet | 6's | 025941 | PKR 170.89 | PKR 28.48/tablet | 38% above median |
| Clozox | Clotrimazole | 500 mg | Tablet | 1's | 025942 | PKR 144.30 | PKR 144.30/tablet | 19% above median |
| Clozox | Clotrimazole | 2% | Vaginal cream | 35gm | 025944 | PKR 180.67 | PKR 5.16/g | 61% above median |
| Clozox | Clotrimazole | 10 mg | Cream | 10gm | 051098 | PKR 127.96 | PKR 12.80/g | 96% above median |
| Contrex | Hydroxyprogesterone caproate | 5 mg | Injection | 2ml | 084375 | PKR 239.54 | PKR 119.77/mL | No comparator |
| Cystexin | Acetylcysteine | 200 mg | Sachet | 1x10's | 123577 | PKR 97.41 | PKR 9.74/sachet | 38% below median |
| Cystexin | Acetylcysteine | 200 mg | Sachet | 20's | 123577 | PKR 194.82 | PKR 9.74/sachet | 38% below median |
| DCad-3 SoftSource observed | Cholecalciferol | 5000 IU | Capsule | 100's | 121805Official source ↗ | No indexed price | — | — |
| Declawin | Daclatasvir | 60 mg | Tablet | 28's | 098355 | PKR 8,405.66 | PKR 300.20/tablet | 7% below median |
| Derivax | Calcipotriol | 50 µg | Cream | 30gm | 094203 | PKR 1,426.39 | PKR 47.55/g | No comparator |
| Dibmet XR | Metformin | 500 mg | Tablet | 50's | 103529 | PKR 108.21 | PKR 2.16/tablet | 20% below median |
| Ditone E2 Viginal | Dinoprostone | 3 mg | Tablet | 4's | 084376 | PKR 3,758.42 | PKR 939.61/tablet | No comparator |
| Ditone E2 Viginal | Dinoprostone | 3 mg | Vaginal tablet | 1's | 084376 | PKR 878.08 | PKR 878.08/tablet | No comparator |
| Ditone F2 | Dinoprostone | 5 mg/1 mL | Injection | 1 ml x 1's | 090270 | PKR 612.48 | PKR 612.48/mL | No comparator |
| Doxycap | Doxycycline | 100 mg | Capsule | 60's | 025940 | PKR 558.06 | PKR 9.30/capsule | 18% above median |
| Doxycap | Doxycycline | 100 mg | Capsule | 10's | 025940 | PKR 95.65 | PKR 9.57/capsule | 22% above median |
| Doxycap | Doxycycline | 100 mg | Capsule | 10x10's | 025940 | PKR 785.79 | PKR 7.86/capsule | Near median |
| Ecad | Elemental Calcium | 400 mg | Tablet | 30's | 049151 | PKR 66.21 | PKR 2.21/tablet | No comparator |
| Embex | Rivaroxaban | 15 mg | Tablet | 14's | 090009 | PKR 1,384.20 | PKR 98.87/tablet | 86% below median |
| Embex | Rivaroxaban | 20 mg | Tablet | 14's | 090010 | PKR 1,730.25 | PKR 123.59/tablet | 86% below median |
| Embex | Rivaroxaban | 10 mg | Tablet | 4x7's | 090011 | PKR 1,882.51 | PKR 67.23/tablet | 88% below median |
| Embex | Rivaroxaban | 10 mg | Tablet | 10's | 090011 | PKR 700.34 | PKR 70.03/tablet | 87% below median |
| Embex DS | Rivaroxaban | 20 mg | Tablet | 4x7's | 090010 | PKR 3,322.08 | PKR 118.65/tablet | 87% below median |
| Embex Forte | Rivaroxaban | 15 mg | Tablet | 4x7's | 090009 | PKR 2,657.67 | PKR 94.92/tablet | 87% below median |
| Emdagan 10 | Empagliflozin | 10 mg | Tablet | 14's | 107160 | PKR 999.96 | PKR 71.43/tablet | 14% below median |
| Emdagan 25 | Empagliflozin | 25 mg | Tablet | 14's | 107161 | PKR 1,196.87 | PKR 85.49/tablet | 15% below median |
| Emdagan Plus | Empagliflozin + Metformin | 5 mg + 850 mg | Tablet | 14's | 110794 | PKR 606.90 | PKR 43.35/tablet | 14% below median |
| Emdagan Plus | Empagliflozin + Metformin | 5 mg + 1000 mg | Tablet | 14's | 110795 | PKR 608.43 | PKR 43.46/tablet | 16% below median |
| Emdagan Plus | Empagliflozin + Metformin | 12.5 mg + 500 mg | Tablet | 14's | 110796 | PKR 707.79 | PKR 50.56/tablet | 8% below median |
| Emdagan Plus | Empagliflozin + Metformin | 12.5 mg + 850 mg | Tablet | 14's | 110797 | PKR 718.50 | PKR 51.32/tablet | 8% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.